Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00596687 · ClinicalTrials.gov registry record · Phase 4
Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
- 234
- Enrollment target
NCT00596687: Completed Phase 4 study, sponsored by Emory University.
NCT00596687 is a Phase 4 study that has completed, run by Emory University. The registered enrollment target is 234 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00596687, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 234 participants
- Enrollment target
Study Summary
High blood glucose levels in surgical patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. In patients who have undergone surgery, high blood glucose increases the risk of wound infection, kidney failure and death. It is not known; however, what is the best insulin regimen in patients who will undergo surgery. The use of repeated injections of regular insulin is commonly used for glucose control in hospitalized patients with diabetes. Recently, the combination of Lantus® and Apidra® insulins has been shown to improve glucose control with lower rate of hypoglycemia (low blood sugar). We hypothesize that in patients with type 2 diabetes admitted to general surgery wards, treatment with once daily glargine (Lantus) plus supplemental glulisine insulin (Apidra®) will produce better glycemic control and a lower rate of hospital complications than treatment with regular insulin per sliding scale (SSRI). The present study aims to determine which insulin treatment is best for glucose control in hospitalized patients with diabetes. Glargine and glulisine insulins are approved for use in the treatment of patients with diabetes by the FDA. Subjects included in the study will have type 2 diabetes and be admitted to Grady Memorial Hospital, Veterans Administration Medical Center, and Emory University Hospital, Atlanta, Georgia. A total of \~94 patients will be recruited at each institution. A post-hoc cost analysis of hospitalization costs and charges of the Rabbit surgery trial will be completed in order to determine differences in hospitalization cost between basal bolus insulin and SSI regimen.
Primary Outcome
blood glucose concentration in the intervention groups after second day of treatment to up to 10 days of treatment
Interventions
- DRUG Insulin glargine
- DRUG Insulin glulisine
- DRUG Regular insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 234 participants |
| Start Date | 2007-12 |
| Est. Completion | 2013-07 |
| Phase | Phase 4 |
What the finished NCT00596687 record still lists
NCT00596687 is an interventional study that assigns participants to a tested intervention. The registered 234 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 3 interventions - of which Insulin glargine is the first listed.
NCT00596687 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00596687 about?
NCT00596687 is a clinical study titled "Basal Bolus Insulin Versus SSRI in Type 2 Diabetes Undergoing General Surgery". High blood glucose levels in surgical patients with diabetes are associated with increased risk of medical complications and death. Improved glucose control with insulin injections may improve clinical outcome and prevent some of the hospital complications. In patients who have undergone surgery, hi...
What is the current status of trial NCT00596687?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 234 participants. The study started on 2007-12. Estimated completion is 2013-07.
What interventions are being tested in trial NCT00596687?
The interventions under investigation include: Insulin glargine (DRUG), Insulin glulisine (DRUG), Regular insulin (DRUG).
Who is sponsoring clinical trial NCT00596687?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00596687's enrollment target sits among peer trials
234 369th of 2000 higher than 1,632 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04942717 · 234 participants · NA
Adapting for Latinx Populations an Intervention That Involves Discussing and Sharing Patients' Health-Related Values
- NCT05208671 · 234 participants · NA
Nutrition to Optimize, Understand, and Restore Insulin Sensitivity in HIV for Oklahoma
- NCT05444465 · 234 participants · NA
Use of the REGENETEN™ Bioinductive Implant System in High Grade Partial-thickness Tears
- NCT05720338 · 234 participants · Phase 3
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia